AIDS Therapies (VIRACEPT)

Patients Who Fail Therapy Not Excluded from Other Treatment Options

Published in AIDS Weekly, February 16th, 1998

Agouron Pharmaceuticals, Inc., La Jolla, California, reported positive results in patients who, after failing treatment with VIRACEPT (nelfinavir mesylate), were treated with other protease inhibitors and experienced favorable anti-HIV responses.

Results from the multicenter study were presented at the Fifth Conference on Retroviruses and Opportunistic Infections, held in Chicago, Illinois, during February 1998.

Pablo Tebas, M.D., Washington University in St. Louis, Missouri, reported an evaluation of 26 patients from key clinical trials of VIRACEPT (studies 506 and 511) who had received VIRACEPT for an average of 55 weeks prior to experiencing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-02-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry